019175.KS
Shin Poong Pharm.Co.,Ltd. [019175.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
019175.KS Stock Summary
Top 019175.KS Correlated Resources
019175.KS
Top 10 Correlated ETFs
019175.KS
Top 10 Correlated Stocks
019175.KS
019175.KS Financial details
Company Rating
Buy
Market Cap
107.33B
Income
-30.7B
Revenue
200.2B
Book val./share
6591.53
Cash/share
-
Dividend
-
Dividend %
-
Employees
815
Optionable
No
Shortable
Yes
Earnings
-
P/E
-80.75
Forward P/E
-
PEG
1.15
P/S
12.38
P/B
7.34
P/C
-
P/FCF
-67.37
Quick Ratio
-
Current Ratio
7.22
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-601.82
EPS next Y
-
EPS next Q
-
EPS this Y
-325%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
0.45%
Revenue Q/Q
5.97%
EPS Q/Q
102.74%
-
-
-
-
SMA20
45.9%
SMA50
41.82%
SMA100
4.22%
Inst Own
-
Inst Trans
-
ROA
-8%
ROE
-9%
ROC
-0.09%
Gross Margin
38%
Oper. Margin
-17%
Profit Margin
-15%
Payout
-
Shs Outstand
1.99M
Shs Float
37.49M
-
-
-
-
Target Price
-
52W Range
28950.0-135000.0
52W High
-64.19%
52W Low
+67.01%
RSI
57
Rel Volume
0.33
Avg Volume
50.81K
Volume
16.7K
Perf Week
17.21%
Perf Month
48.77%
Perf Quarter
19.68%
Perf Half Y
0.73%
-
-
-
-
Beta
1.25205
-
-
Volatility
5099.91%, 9857.36%
Prev Close
-1.93%
Price
48350
Change
-10.79%
019175.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.86K | 3.91K | 3.95K | 4.09K | 3.68K | |
| Net income per share | 18.86 | 58.43 | 110.96 | 103.5 | -225 | |
| Operating cash flow per share | 211.5 | 668.06 | 403.29 | 415.05 | -1.38K | |
| Free cash flow per share | 137.34 | 629.72 | 107.77 | 350.5 | -1.49K | |
| Cash per share | 801.92 | 1.39K | 1.38K | 3.94K | 1.8K | |
| Book value per share | 4.37K | 4.3K | 4.34K | 7.72K | 6.87K | |
| Tangible book value per share | 4.2K | 4.18K | 4.17K | 7.58K | 6.71K | |
| Share holders equity per share | 4.37K | 4.3K | 4.34K | 7.72K | 6.87K | |
| Interest debt per share | 2.44K | 2.33K | 2.31K | 97.86 | 26.86 | |
| Market cap | 253.34B | 309B | 323.87B | 3910.49B | 1742.69B | |
| Enterprise value | 346.49B | 379.27B | 406.99B | 3856.47B | 1716.23B | |
| P/E ratio | 279.97 | 110.21 | 60.83 | 781.66 | -150.44 | |
| Price to sales ratio | 1.37 | 1.65 | 1.71 | 19.77 | 9.21 | |
| POCF ratio | 24.96 | 9.64 | 16.74 | 194.92 | -24.54 | |
| PFCF ratio | 38.45 | 10.23 | 62.64 | 230.81 | -22.74 | |
| P/B Ratio | 1.21 | 1.5 | 1.56 | 10.47 | 4.93 | |
| PTB ratio | 1.21 | 1.5 | 1.56 | 10.47 | 4.93 | |
| EV to sales | 1.87 | 2.02 | 2.15 | 19.5 | 9.07 | |
| Enterprise value over EBITDA | 21.65 | 18.22 | 17.34 | 164.45 | 447.62 | |
| EV to operating cash flow | 34.14 | 11.83 | 21.03 | 192.22 | -24.16 | |
| EV to free cash flow | 52.58 | 12.55 | 78.71 | 227.62 | -22.39 | |
| Earnings yield | 0 | 0.01 | 0.02 | 0 | -0.01 | |
| Free cash flow yield | 0.03 | 0.1 | 0.02 | 0 | -0.04 | |
| Debt to equity | 0.05 | 0.01 | 0.04 | 0 | 0 | |
| Debt to assets | 0.46 | 0.46 | 0.45 | 0.23 | 0.1 | |
| Net debt to EBITDA | 5.82 | 3.38 | 3.54 | -2.3 | -6.9 | |
| Current ratio | 1.54 | 1.54 | 1.64 | 3.99 | 7.96 | |
| Interest coverage | 1.75 | 1.81 | 1.36 | 2.66 | -70.8 | |
| Income quality | 11.21 | 11.43 | 3.63 | 4.01 | 6.13 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | -0.45 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.09 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.35 | -0.06 | -0.73 | -0.16 | 0.08 | |
| Capex to revenue | -0.02 | -0.01 | -0.07 | -0.02 | -0.03 | |
| Capex to depreciation | -0.36 | -0.16 | -1.15 | -0.26 | -0.44 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.36K | 2.38K | 3.29K | 4.24K | 5.9K | |
| ROIC | 0.03 | 0.03 | 0.02 | 0.02 | -0.04 | |
| Return on tangible assets | 0 | 0.01 | 0.01 | 0.01 | -0.03 | |
| Graham Net | -2.37K | -1.76K | -1.67K | 2.12K | 1.53K | |
| Working capital | 74.74B | 78.44B | 85.24B | 249.47B | 198.68B | |
| Tangible asset value | 201.33B | 200.36B | 200.21B | 366.27B | 345.59B | |
| Net current asset value | 38.31B | 51.14B | 48.21B | 219.99B | 189.21B | |
| Invested capital | 0.54 | 0.52 | 0.51 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 16.98B | 14.98B | 13.58B | 8.79B | 10.42B | |
| Average inventory | 48.01B | 47.01B | 49.06B | 49.09B | 48.4B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 87.62 | 69.28 | 59.07 | 26.46 | 39.36 | |
| Days of inventory on hand | 163.33 | 147.1 | 157.61 | 147.8 | 155.68 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.17 | 5.27 | 6.18 | 13.79 | 9.27 | |
| Inventory turnover | 2.23 | 2.48 | 2.32 | 2.47 | 2.34 | |
| ROE | 0 | 0.01 | 0.03 | 0.01 | -0.03 | |
| Capex per share | -74.16 | -38.34 | -295.53 | -64.55 | -109.06 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 956.63 | 982.74 | 911.73 | 982.27 | 1.04K | |
| Net income per share | -39 | -226.29 | -104 | -89.69 | -181.83 | |
| Operating cash flow per share | -46.54 | -440.97 | -108.82 | 83.87 | -126.85 | |
| Free cash flow per share | -70.12 | -470.19 | -131.41 | 27.83 | -150.26 | |
| Cash per share | 2.66K | 1.83K | 1.64K | 0 | 0 | |
| Book value per share | 7.23K | 6.99K | 6.79K | 6.71K | 6.59K | |
| Tangible book value per share | 7.09K | 6.83K | 6.67K | 6.73K | 6.62K | |
| Share holders equity per share | 7.23K | 6.99K | 6.79K | 6.71K | 6.59K | |
| Interest debt per share | 29.07 | 23.57 | 30.95 | 3.75 | 45.66 | |
| Market cap | 4076.86B | 2023.26B | 4045.75B | 2051.08B | 1610.09B | |
| Enterprise value | 4026.6B | 1996.8B | 4017.2B | 2051.08B | 1610.09B | |
| P/E ratio | -516.67 | -44.19 | -189.66 | -111.5 | -43.17 | |
| Price to sales ratio | 84.25 | 40.7 | 86.54 | 40.72 | 30.16 | |
| POCF ratio | -1.73K | -90.71 | -725.04 | 476.91 | -247.53 | |
| PFCF ratio | -1.15K | -85.07 | -600.42 | 1.44K | -208.97 | |
| P/B Ratio | 11.15 | 5.72 | 11.62 | 5.96 | 4.76 | |
| PTB ratio | 11.15 | 5.72 | 11.62 | 5.96 | 4.76 | |
| EV to sales | 83.22 | 40.17 | 85.93 | 40.72 | 30.16 | |
| Enterprise value over EBITDA | 12.2K | -404.13 | -986.39 | -754.3 | -157.72 | |
| EV to operating cash flow | -1.71K | -89.52 | -719.92 | 476.91 | -247.53 | |
| EV to free cash flow | -1.14K | -83.96 | -596.18 | 1.44K | -208.97 | |
| Earnings yield | 0 | -0.01 | 0 | 0 | -0.01 | |
| Free cash flow yield | 0 | -0.01 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.12 | 0.1 | 0.1 | 0.11 | 0.11 | |
| Net debt to EBITDA | -152.27 | 5.35 | 7.01 | 0 | 0 | |
| Current ratio | 8.64 | 7.96 | 8.01 | 6.86 | 7.22 | |
| Interest coverage | -73.03 | -752.73 | -1.04K | -17.86 | -6.06 | |
| Income quality | 1.19 | 1.95 | 1.05 | -0.94 | 0.7 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.45 | 0.63 | |
| Research and developement to revenue | 0.12 | 0.1 | 0.11 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0 | 0 | |
| Capex to operating cash flow | 0.51 | 0.07 | 0.21 | -0.67 | 0.18 | |
| Capex to revenue | -0.02 | -0.03 | -0.02 | -0.06 | -0.02 | |
| Capex to depreciation | -0.38 | -0.44 | -0.36 | -0.87 | -0.37 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.52K | 5.97K | 3.99K | 3.68K | 5.19K | |
| ROIC | -0.01 | -0.02 | -0.02 | -0.01 | -0.04 | |
| Return on tangible assets | 0 | -0.03 | -0.01 | -0.01 | -0.02 | |
| Graham Net | 2.16K | 1.55K | 1.37K | -841.34 | -802.99 | |
| Working capital | 237.99B | 198.68B | 196.06B | 189.89B | 185.65B | |
| Tangible asset value | 358.69B | 345.59B | 341.83B | 0 | 0 | |
| Net current asset value | 219.9B | 189.21B | 184.73B | 179.15B | 174.33B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 38.92 | 36.11 | 37.95 | 0 | 0 | |
| Days of inventory on hand | 149.59 | 142.82 | 154.19 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.31 | 2.49 | 2.37 | 0 | 0 | |
| Inventory turnover | 0.6 | 0.63 | 0.58 | 0 | 0 | |
| ROE | -0.01 | -0.03 | -0.02 | -0.01 | -0.03 | |
| Capex per share | -23.58 | -29.22 | -22.59 | -56.04 | -23.4 |
019175.KS Frequently Asked Questions
What is Shin Poong Pharm.Co.,Ltd. stock symbol ?
Shin Poong Pharm.Co.,Ltd. is a US stock and trading under the symbol 019175.KS
What is Shin Poong Pharm.Co.,Ltd. stock quote today ?
Shin Poong Pharm.Co.,Ltd. stock price is $48350 today.
Is Shin Poong Pharm.Co.,Ltd. stock public?
Yes, Shin Poong Pharm.Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 50.81K
- Market Capitalization 107.33B
- Employee 815
- Headquarters Seoul,US
- IPO Date 2005-09-29
-
Website
https://shinpoong.co.kr 
Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
